About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Therapeutic Advances in Neurological Disorders
›
top-articles
Therapeutic Advances in Neurological Disorders
4.7
(top 5%)
impact factor
732
(top 20%)
papers
20.0K
(top 10%)
citations
70
(top 10%)
h
-index
4.9
(top 5%)
impact factor
860
all documents
21.9K
doc citations
102
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Current and future treatments for Alzheimer’s disease
Therapeutic Advances in Neurological Disorders
2013
478
2
Sex and gender issues in multiple sclerosis
Therapeutic Advances in Neurological Disorders
2013
368
3
The cognitive impact of antiepileptic drugs
Therapeutic Advances in Neurological Disorders
2011
289
4
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Therapeutic Advances in Neurological Disorders
2021
259
5
Assessment scales in dementia
Therapeutic Advances in Neurological Disorders
2012
244
6
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Therapeutic Advances in Neurological Disorders
2015
240
7
Best practice in the management of behavioural and psychological symptoms of dementia
Therapeutic Advances in Neurological Disorders
2017
195
8
Review: Deep brain stimulation in Parkinson’s disease
Therapeutic Advances in Neurological Disorders
2009
176
9
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives
Therapeutic Advances in Neurological Disorders
2015
175
10
Danger signals in stroke and their role on microglia activation after ischemia
Therapeutic Advances in Neurological Disorders
2018
165
11
Myoclonic disorders: a practical approach for diagnosis and treatment
Therapeutic Advances in Neurological Disorders
2011
159
12
Potential neurological symptoms of COVID-19
Therapeutic Advances in Neurological Disorders
2020
158
13
Treatment strategies for autoimmune encephalitis
Therapeutic Advances in Neurological Disorders
2018
156
14
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Therapeutic Advances in Neurological Disorders
2012
152
15
Treatment options in trigeminal neuralgia
Therapeutic Advances in Neurological Disorders
2010
150
16
Review: Diagnosis and treatment of cerebral vasculitis
Therapeutic Advances in Neurological Disorders
2010
147
17
Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
Therapeutic Advances in Neurological Disorders
2015
145
18
Defining distinct features of anti-MOG antibody associated central nervous system demyelination
Therapeutic Advances in Neurological Disorders
2018
137
19
Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
Therapeutic Advances in Neurological Disorders
2018
136
20
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Therapeutic Advances in Neurological Disorders
2015
134
21
Review: Blood pressure and dementia — a comprehensive review
Therapeutic Advances in Neurological Disorders
2009
133
22
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
Therapeutic Advances in Neurological Disorders
2012
132
23
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
Therapeutic Advances in Neurological Disorders
2011
131
24
Treatment strategies for tics in Tourette syndrome
Therapeutic Advances in Neurological Disorders
2011
130
25
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
Therapeutic Advances in Neurological Disorders
2018
129
26
Review: Pathophysiology and treatment of bacterial meningitis
Therapeutic Advances in Neurological Disorders
2009
128
27
Smoking: effects on multiple sclerosis susceptibility and disease progression
Therapeutic Advances in Neurological Disorders
2012
126
28
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
Therapeutic Advances in Neurological Disorders
2010
125
29
Treatment of glioblastoma in adults
Therapeutic Advances in Neurological Disorders
2018
117
30
Neurological manifestations and implications of COVID-19 pandemic
Therapeutic Advances in Neurological Disorders
2020
114
31
Current and emerging therapies in multiple sclerosis: a systematic review
Therapeutic Advances in Neurological Disorders
2012
112
32
Atacicept: targeting B cells in multiple sclerosis
Therapeutic Advances in Neurological Disorders
2010
111
33
A review of the use of magnetic resonance imaging in Parkinson’s disease
Therapeutic Advances in Neurological Disorders
2014
111
34
Disease-modifying treatments for Alzheimer’s disease
Therapeutic Advances in Neurological Disorders
2011
110
35
Repetitive transcranial magnetic stimulation in stroke rehabilitation: review of the current evidence and pitfalls
Therapeutic Advances in Neurological Disorders
2019
109
36
Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited
Therapeutic Advances in Neurological Disorders
2008
107
37
Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency
Therapeutic Advances in Neurological Disorders
2010
106
38
Anxiety in Parkinson’s disease: identification and management
Therapeutic Advances in Neurological Disorders
2014
106
39
Current approaches to the treatment of paraneoplastic encephalitis
Therapeutic Advances in Neurological Disorders
2011
105
40
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
Therapeutic Advances in Neurological Disorders
2013
103
41
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
Therapeutic Advances in Neurological Disorders
2016
103
42
Antisense oligonucleotides in neurological disorders
Therapeutic Advances in Neurological Disorders
2018
100
43
MRI in the assessment and monitoring of multiple sclerosis: an update on best practice
Therapeutic Advances in Neurological Disorders
2017
99
44
Magnetic resonance monitoring of lesion evolution in multiple sclerosis
Therapeutic Advances in Neurological Disorders
2013
98
45
Review: Therapy for Alzheimer's disease: how effective are current treatments?
Therapeutic Advances in Neurological Disorders
2009
95
46
Management of women with multiple sclerosis through pregnancy and after childbirth
Therapeutic Advances in Neurological Disorders
2016
92
47
Management of sexual dysfunction in Parkinson’s disease
Therapeutic Advances in Neurological Disorders
2011
91
48
An update on best practice of deep brain stimulation in Parkinson’s disease
Therapeutic Advances in Neurological Disorders
2019
91
49
Management of vestibular migraine
Therapeutic Advances in Neurological Disorders
2011
90
50
Ocrelizumab: a new milestone in multiple sclerosis therapy
Therapeutic Advances in Neurological Disorders
2018
90
site/software ©
exaly
; All materials licenced under
CC by-SA
.